Falchook G - Search Results

1

A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.

Falchook G, Patnaik A, Richardson DL, Harvey RD, Sharma MR, Hafez N, Hamilton E, Piha-Paul SA, Barve M, Wise-Draper T, Patel MR, Dowlati A, Pascuzzo J, Tang SC, Faltermeier C, Malinowska IA, Shtessel L, Striha A, Potocka E. Falchook G, et al. Clin Ther. 2024 Mar;46(3):228-238. doi: 10.1016/j.clinthera.2024.01.004. Epub 2024 Feb 28. Clin Ther. 2024. PMID: 38423866 Free article. Clinical Trial.

2

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. Janku F, et al. Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7. Mol Cancer Ther. 2011. PMID: 21216929 Free PMC article.

3

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.

Wheler J, Tsimberidou AM, Hong D, Naing A, Falchook G, Piha-Paul S, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R. Wheler J, et al. Among authors: falchook g. Clin Cancer Res. 2012 May 15;18(10):2922-9. doi: 10.1158/1078-0432.CCR-11-2217. Epub 2012 Mar 27. Clin Cancer Res. 2012. PMID: 22452943 Free PMC article.

4

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.

Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Tolcher AW, et al. Among authors: falchook gs. J Clin Oncol. 2012 Jul 1;30(19):2348-53. doi: 10.1200/JCO.2011.36.8282. Epub 2012 Apr 23. J Clin Oncol. 2012. PMID: 22529266 Free PMC article. Clinical Trial.

5

Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience.

Fu S, Barber FD, Naing A, Wheler J, Hong D, Falchook G, Piha-Paul S, Tsimberidou A, Howard A, Kurzrock R. Fu S, et al. Among authors: falchook g. J Clin Oncol. 2012 Aug 10;30(23):2891-6. doi: 10.1200/JCO.2011.38.0758. Epub 2012 Jul 9. J Clin Oncol. 2012. PMID: 22778314 Clinical Trial.

6

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Tsimberidou AM, et al. Among authors: falchook gs. Clin Cancer Res. 2012 Nov 15;18(22):6373-83. doi: 10.1158/1078-0432.CCR-12-1627. Epub 2012 Sep 10. Clin Cancer Res. 2012. PMID: 22966018 Free PMC article.

7

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. Janku F, et al. Cancer Res. 2013 Jan 1;73(1):276-84. doi: 10.1158/0008-5472.CAN-12-1726. Epub 2012 Oct 12. Cancer Res. 2013. PMID: 23066039 Free PMC article.

8

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.

Wheler JJ, Falchook GS, Tsimberidou AM, Hong DS, Naing A, Piha-Paul SA, Chen SS, Fu S, Stephen B, Fok JY, Janku F, Kurzrock R. Wheler JJ, et al. Among authors: falchook gs. Ann Oncol. 2013 Mar;24(3):838-42. doi: 10.1093/annonc/mds524. Epub 2012 Nov 8. Ann Oncol. 2013. PMID: 23139256 Free PMC article.

9

Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver.

Tsimberidou AM, Leick MB, Lim J, Fu S, Wheler J, Piha-Paul SA, Hong D, Falchook GS, Naing A, Subbiah IM, Fortier A, Avritscher R, Kurzrock R. Tsimberidou AM, et al. Cancer Chemother Pharmacol. 2013 Feb;71(2):389-97. doi: 10.1007/s00280-012-2014-8. Epub 2012 Nov 11. Cancer Chemother Pharmacol. 2013. PMID: 23143207 Clinical Trial.

10

A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.

Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. Hong DS, et al. Invest New Drugs. 2013 Aug;31(4):918-26. doi: 10.1007/s10637-012-9898-3. Epub 2012 Nov 20. Invest New Drugs. 2013. PMID: 23179336 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page